Cargando…

High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

Blinatumomab is a bispecific T-cell engager approved for B-cell precursor acute lymphoblastic leukemia (B-ALL) with persistent minimal residual disease (MRD) or in relapse. The prognostic impact of tumor load has been suggested before other immunotherapies but remains poorly explored before blinatum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabannes-Hamy, Aurélie, Brissot, Eolia, Leguay, Thibaut, Huguet, Françoise, Chevallier, Patrice, Hunault, Mathilde, Escoffre-Barbe, Martine, Cluzeau, Thomas, Balsat, Marie, Nguyen, Stéphanie, Pasquier, Florence, Alexis, Magda, Lhéritier, Véronique, Pastoret, Cédric, Delabesse, Eric, Clappier, Emmanuelle, Dombret, Hervé, Boissel, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Acute Lymphoblastic Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425331/ https://www.ncbi.nlm.nih.gov/pubmed/35263986 http://dx.doi.org/10.3324/haematol.2021.280078

Ejemplares similares

Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study
por: Orvain, Corentin, et al.
Publicado: (2023)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022)

CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
por: Trajkova, Sanja, et al.
Publicado: (2022)

ALL-083 ALLogeneic Hematopoietic Stem Cell Transplantation of a R/R T-ALL Patient Given Nelarabine, 3 Weeks Post Moderate COVID-19 Infection in the Local Setting
por: Uong, Flaryll
Publicado: (2022)

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

ALL-206 Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country
por: Hammad, Mahmoud, et al.
Publicado: (2022)

CLL-393 Outcomes of COVID-19 Infections in Patients With Hematological Malignancies in Republic of North Macedonia
por: Cvetanoski, Milche, et al.
Publicado: (2022)

AML-174 Dilemma of Treating Acute Myeloid Leukemia Patient After Kidney Transplant in the COVID-19 Era
por: El-Ashwah, Shaimaa, et al.
Publicado: (2022)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial
por: Paillassa, Jérôme, et al.
Publicado: (2018)

Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T-cell acute lymphoblastic leukemia cells
por: Kuzilková, Daniela, et al.
Publicado: (2021)

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
por: Kayser, Sabine, et al.
Publicado: (2022)

Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials
por: Creasey, Thomas, et al.
Publicado: (2021)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
por: Thielemans, Naomi, et al.
Publicado: (2022)

Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes
por: Anastasopoulou, Stavroula, et al.
Publicado: (2022)

Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)
por: Tasian, Sarah K., et al.
Publicado: (2022)

In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia
por: Van Trimpont, Maaike, et al.
Publicado: (2022)

Genome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia
por: Lalonde, Marie-Eve, et al.
Publicado: (2022)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia
por: Lim, Fang Qi, et al.
Publicado: (2022)

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement
por: Bomken, Simon, et al.
Publicado: (2022)

STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of BCL and BCLXL following glucocorticoid treatment
por: van der Zwet, Jordy C.G., et al.
Publicado: (2022)

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Wayne, Alan S., et al.
Publicado: (2022)

Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade
por: Woess, Katharina, et al.
Publicado: (2022)

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
por: González-Gil, Celia, et al.
Publicado: (2022)

Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia
por: Masic, Dino, et al.
Publicado: (2022)

General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
por: Gökbuget, Nicola, et al.
Publicado: (2023)

B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow
por: Barz, Malwine J., et al.
Publicado: (2022)

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3’ neo-enhancer
por: Smith, Charlotte, et al.
Publicado: (2023)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

RNA helicase DHX15 exemplifies a unique dependency in acute leukemia
por: Guo, Hao, et al.
Publicado: (2023)

Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia
por: Heilmann, Janina, et al.
Publicado: (2023)

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study
por: Desjonquères, A, et al.
Publicado: (2016)

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups
por: Ribera, Josep-Maria, et al.
Publicado: (2020)

Newly Diagnosed Acute Lymphoblastic Leukemia in a Child with COVID-19 Complicated By MIS-C: A Case Report from Kuwait
por: Al-Haddad, Fatemah, et al.
Publicado: (2020)

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report
por: Chiaretti, Sabina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f33rm0nvpcfimjtq149rnjv08i